x
|
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarter Ended September 27, 2014
|
o
|
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Delaware
|
04-2209186
|
(State of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
81 Wyman Street
|
|
Waltham, Massachusetts
|
02451
|
(Address of principal executive offices)
|
(Zip Code)
|
Class
|
Outstanding at September 27, 2014
|
|
Common Stock, $1.00 par value
|
400,025,475
|
TABLE OF CONTENTS
|
||
Page
|
||
PART I
|
||
Item 1.
|
Financial Statements (Unaudited)
|
3
|
Item 2.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
35
|
Item 3.
|
Quantitative and Qualitative Disclosures About Market Risk
|
49
|
Item 4.
|
Controls and Procedures
|
49
|
PART II
|
||
Item 1.
|
Legal Proceedings
|
51
|
Item 1A.
|
Risk Factors
|
51
|
Item 2.
|
Unregistered Sales of Equity Securities and Use of Proceeds
|
57
|
Item 6.
|
Exhibits
|
57
|
PART I FINANCIAL INFORMATION
|
Item 1. Financial Statements
|
September 27,
|
December 31,
|
|||||||
(In millions)
|
2014
|
2013
|
||||||
Assets
|
||||||||
Current Assets:
|
||||||||
Cash and cash equivalents
|
$ | 534.3 | $ | 5,826.0 | ||||
Short-term investments
|
9.3 | 4.5 | ||||||
Accounts receivable, less allowances of $78.5 and $54.1
|
2,507.1 | 1,942.3 | ||||||
Inventories
|
1,913.7 | 1,494.5 | ||||||
Deferred tax assets
|
230.6 | 192.5 | ||||||
Other current assets
|
524.9 | 420.9 | ||||||
Total current assets
|
5,719.9 | 9,880.7 | ||||||
Property, Plant and Equipment, at Cost, Net
|
2,406.1 | 1,767.4 | ||||||
Acquisition-related Intangible Assets, Net
|
14,698.3 | 7,071.3 | ||||||
Other Assets
|
819.7 | 640.7 | ||||||
Goodwill
|
19,046.8 | 12,503.3 | ||||||
Total Assets
|
$ | 42,690.8 | $ | 31,863.4 |
September 27,
|
December 31,
|
|||||||
(In millions except share amounts)
|
2014
|
2013
|
||||||
Liabilities and Shareholders' Equity
|
||||||||
Current Liabilities:
|
||||||||
Short-term obligations and current maturities of long-term obligations
|
$ | 3,088.5 | $ | 987.7 | ||||
Accounts payable
|
818.1 | 691.5 | ||||||
Accrued payroll and employee benefits
|
627.8 | 432.0 | ||||||
Accrued income taxes
|
324.0 | — | ||||||
Deferred revenue
|
325.9 | 198.9 | ||||||
Other accrued expenses
|
1,037.8 | 815.9 | ||||||
Total current liabilities
|
6,222.1 | 3,126.0 | ||||||
Deferred Income Taxes
|
3,473.1 | 1,609.9 | ||||||
Other Long-term Liabilities
|
1,096.4 | 771.8 | ||||||
Long-term Obligations
|
11,388.6 | 9,499.6 | ||||||
Shareholders' Equity:
|
||||||||
Preferred stock, $100 par value, 50,000 shares authorized; none issued
|
||||||||
Common stock, $1 par value, 1,200,000,000 shares authorized; 408,013,012 and 369,598,265 shares issued
|
408.0 | 369.6 | ||||||
Capital in excess of par value
|
11,416.3 | 8,222.6 | ||||||
Retained earnings
|
9,866.0 | 8,753.3 | ||||||
Treasury stock at cost, 7,987,537 and 7,636,887 shares
|
(455.4 | ) | (412.2 | ) | ||||
Accumulated other comprehensive items
|
(724.3 | ) | (77.2 | ) | ||||
Total shareholders' equity
|
20,510.6 | 16,856.1 | ||||||
Total Liabilities and Shareholders' Equity
|
$ | 42,690.8 | $ | 31,863.4 |
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
September 27,
|
September 28,
|
September 27,
|
September 28,
|
|||||||||||||
(In millions except per share amounts)
|
2014
|
2013
|
2014
|
2013
|
||||||||||||
Revenues
|
||||||||||||||||
Product revenues
|
$ | 3,628.5 | $ | 2,730.8 | $ | 10,781.9 | $ | 8,241.1 | ||||||||
Service revenues
|
542.9 | 461.0 | 1,614.9 | 1,382.3 | ||||||||||||
Total revenues
|
4,171.4 | 3,191.8 | 12,396.8 | 9,623.4 | ||||||||||||
Costs and Operating Expenses:
|
||||||||||||||||
Cost of product revenues
|
1,873.9 | 1,546.6 | 5,920.1 | 4,652.2 | ||||||||||||
Cost of service revenues
|
363.9 | 297.3 | 1,076.6 | 923.8 | ||||||||||||
Selling, general and administrative expenses
|
1,228.7 | 848.5 | 3,659.5 | 2,547.6 | ||||||||||||
Research and development expenses
|
175.2 | 95.9 | 508.6 | 290.8 | ||||||||||||
Restructuring and other costs (income), net
|
(110.6 | ) | 11.4 | (631.9 | ) | 54.4 | ||||||||||
Total costs and operating expenses
|
3,531.1 | 2,799.7 | 10,532.9 | 8,468.8 | ||||||||||||
Operating Income
|
640.3 | 392.1 | 1,863.9 | 1,154.6 | ||||||||||||
Other Expense, Net
|
(101.1 | ) | (73.1 | ) | (313.8 | ) | (212.7 | ) | ||||||||
Income from Continuing Operations Before Income Taxes
|
539.2 | 319.0 | 1,550.1 | 941.9 | ||||||||||||
Income Tax Provision
|
(69.3 | ) | (1.3 | ) | (258.6 | ) | (5.8 | ) | ||||||||
Income from Continuing Operations
|
469.9 | 317.7 | 1,291.5 | 936.1 | ||||||||||||
Gain (Loss) from Discontinued Operations (net of income tax provision (benefit) of
$1.0, ($0.1), $1.0 and ($0.4))
|
1.7 | (0.1 | ) | 1.7 | (0.7 | ) | ||||||||||
Loss on Disposal of Discontinued Operations, Net (net of income tax benefit of $2.8)
|
— | — | — | (4.2 | ) | |||||||||||
Net Income
|
$ | 471.6 | $ | 317.6 | $ | 1,293.2 | $ | 931.2 | ||||||||
Earnings per Share from Continuing Operations
|
||||||||||||||||
Basic
|
$ | 1.17 | $ | .88 | $ | 3.25 | $ | 2.60 | ||||||||
Diluted
|
$ | 1.16 | $ | .86 | $ | 3.21 | $ | 2.57 | ||||||||
Earnings per Share
|
||||||||||||||||
Basic
|
$ | 1.18 | $ | .88 | $ | 3.25 | $ | 2.59 | ||||||||
Diluted
|
$ | 1.17 | $ | .86 | $ | 3.22 | $ | 2.56 | ||||||||
Weighted Average Shares
|
||||||||||||||||
Basic
|
399.9 | 361.2 | 397.5 | 359.8 | ||||||||||||
Diluted
|
403.7 | 367.3 | 401.7 | 364.1 | ||||||||||||
Cash Dividends Declared per Common Share
|
$ | .15 | $ | .15 | $ | .45 | $ | .45 |
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
September 27,
|
September 28,
|
September 27,
|
September 28,
|
|||||||||||||
(In millions)
|
2014
|
2013
|
2014
|
2013
|
||||||||||||
Comprehensive Income (Loss)
|
||||||||||||||||
Net Income
|
$ | 471.6 | $ | 317.6 | $ | 1,293.2 | $ | 931.2 | ||||||||
Other Comprehensive Items:
|
||||||||||||||||
Currency translation adjustment
|
(619.5 | ) | 308.8 | (655.9 | ) | (6.2 | ) | |||||||||
Unrealized gains on available-for-sale investments:
|
||||||||||||||||
Unrealized holding gains (losses) arising during the period (net of tax provision
(benefit) of ($0.2), $0.1, ($0.1) and $0.4)
|
(0.1 | ) | 0.1 | 1.7 | 1.2 | |||||||||||
Reclassification adjustment for gains included in net income (net of tax provision
of $0.0 and $2.5)
|
— | — | (1.4 | ) | (8.0 | ) | ||||||||||
Unrealized gains and losses on hedging instruments:
|
||||||||||||||||
Unrealized gain (loss) on hedging instruments (net of tax provision (benefit) of
($1.1) and $3.0)
|
— | (1.7 | ) | — | 5.0 | |||||||||||
Reclassification adjustment for losses included in net income (net of tax benefit
of $0.5, $0.6, $1.4 and $1.6)
|
0.7 | 0.8 | 2.2 | 2.4 | ||||||||||||
Pension and other postretirement benefit liability adjustment:
|
||||||||||||||||
Pension and other postretirement benefit liability adjustments arising during the
period (net of tax provision (benefit) of $2.1, ($1.7), $1.2 and ($0.2))
|
4.9 | (4.4 | ) | 2.3 | (0.2 | ) | ||||||||||
Amortization of net loss and prior service benefit included in net periodic pension
cost (net of tax benefit of $0.5, $0.8, $1.7 and $2.6)
|
1.4 | 2.0 | 4.0 | 5.8 | ||||||||||||
Total other comprehensive items
|
(612.6 | ) | 305.6 | (647.1 | ) | — | ||||||||||
Comprehensive Income (Loss)
|
$ | (141.0 | ) | $ | 623.2 | $ | 646.1 | $ | 931.2 |
Nine Months Ended
|
||||||||
September 27,
|
September 28,
|
|||||||
(In millions)
|
2014
|
2013
|
||||||
Operating Activities
|
||||||||
Net income
|
$ | 1,293.2 | $ | 931.2 | ||||
(Gain) loss from discontinued operations
|
(1.7 | ) | 0.7 | |||||
Loss on disposal of discontinued operations
|
— | 4.2 | ||||||
Income from continuing operations
|
1,291.5 | 936.1 | ||||||
Adjustments to reconcile income from continuing operations to net cash provided by operating activities:
|
||||||||
Depreciation and amortization
|
1,256.1 | 750.6 | ||||||
Change in deferred income taxes
|
(583.8 | ) | (204.5 | ) | ||||
Net gains on sale of businesses
|
(894.4 | ) | — | |||||
Non-cash stock-based compensation
|
86.6 | 66.6 | ||||||
Tax benefits from stock-based compensation awards
|
(61.1 | ) | (39.8 | ) | ||||
Non-cash charges for sale of inventories revalued at the date of acquisition
|
303.1 | 23.9 | ||||||
Other non-cash expenses, net
|
27.8 | 17.0 | ||||||
Changes in assets and liabilities, excluding the effects of acquisitions and dispositions:
|
||||||||
Accounts receivable
|
(117.3 | ) | (155.3 | ) | ||||
Inventories
|
(109.1 | ) | (129.7 | ) | ||||
Other assets
|
205.8 | (69.0 | ) | |||||
Accounts payable
|
(3.3 | ) | 49.1 | |||||
Other liabilities
|
304.8 | 66.1 | ||||||
Contributions to retirement plans
|
(37.3 | ) | (25.6 | ) | ||||
Net cash provided by continuing operations
|
1,669.4 | 1,285.5 | ||||||
Net cash used in discontinued operations
|
(3.5 | ) | (3.3 | ) | ||||
Net cash provided by operating activities
|
1,665.9 | 1,282.2 | ||||||
Investing Activities
|
||||||||
Acquisitions, net of cash acquired
|
(13,056.1 | ) | (5.5 | ) | ||||
Purchase of property, plant and equipment
|
(270.9 | ) | (187.9 | ) | ||||
Proceeds from sale of property, plant and equipment
|
19.7 | 15.9 | ||||||
Proceeds from sale of investments
|
84.4 | 0.5 | ||||||
Proceeds from sale of businesses, net of cash divested
|
1,520.0 | — | ||||||
Decrease (increase) in restricted cash
|
50.2 | (24.7 | ) | |||||
Other investing activities, net
|
(4.0 | ) | 8.4 | |||||
Net cash used in investing activities
|
$ | (11,656.7 | ) | $ | (193.3 | ) |
Nine Months Ended
|
||||||||
September 27,
|
September 28,
|
|||||||
(In millions)
|
2014
|
2013
|
||||||
Financing Activities
|
||||||||
Net proceeds from issuance of long-term debt
|
$ | 4,999.6 | $ | — | ||||
Increase in commercial paper, net
|
212.2 | — | ||||||
Repayment of long-term obligations
|
(3,430.3 | ) | (0.9 | ) | ||||
Decrease in short-term notes payable
|
(28.2 | ) | (0.7 | ) | ||||
Purchases of company common stock
|
— | (89.8 | ) | |||||
Dividends paid
|
(174.8 | ) | (162.0 | ) | ||||
Net proceeds from issuance of company common stock
|
2,942.0 | — | ||||||
Net proceeds from issuance of company common stock under employee stock plans
|
132.7 | 204.9 | ||||||
Tax benefits from stock-based compensation awards
|
61.1 | 39.8 | ||||||
Other financing activities, net
|
(7.5 | ) | (4.8 | ) | ||||
Net cash provided by (used in) financing activities
|
4,706.8 | (13.5 | ) | |||||
Exchange Rate Effect on Cash
|
(7.7 | ) | (35.4 | ) | ||||
(Decrease) Increase in Cash and Cash Equivalents
|
(5,291.7 | ) | 1,040.0 | |||||
Cash and Cash Equivalents at Beginning of Period
|
5,826.0 | 805.6 | ||||||
Cash and Cash Equivalents at End of Period
|
$ | 534.3 | $ | 1,845.6 |
Accumulated
|
||||||||||||||||||||||||||||||||
Capital in
|
Other
|
Total
|
||||||||||||||||||||||||||||||
Common Stock
|
Excess of
|
Retained
|
Treasury Stock
|
Comprehensive
|
Shareholders'
|
|||||||||||||||||||||||||||
(In millions)
|
Shares
|
Amount
|
Par Value
|
Earnings
|
Shares
|
Amount
|
Items
|
Equity
|
||||||||||||||||||||||||
Balance at December 31, 2012
|
413.5 | $ | 413.5 | $ | 10,501.1 | $ | 7,697.3 | (56.0 | ) | $ | (2,996.8 | ) | $ | (150.4 | ) | $ | 15,464.7 | |||||||||||||||
Issuance of shares under employees'
and directors' stock plans
|
5.5 | 5.5 | 208.0 | — | (0.3 | ) | (22.9 | ) | — | 190.6 | ||||||||||||||||||||||
Stock-based compensation
|
— | — | 66.6 | — | — | — | — | 66.6 | ||||||||||||||||||||||||
Tax benefit related to employees'
and directors' stock plans
|
— | — | 37.6 | — | — | — | — | 37.6 | ||||||||||||||||||||||||
Purchases of company common
stock
|
— | — | — | — | (1.3 | ) | (89.8 | ) | — | (89.8 | ) | |||||||||||||||||||||
Dividends declared
|
— | — | — | (162.8 | ) | — | — | — | (162.8 | ) | ||||||||||||||||||||||
Net income
|
— | — | — | 931.2 | — | — | — | 931.2 | ||||||||||||||||||||||||
Other comprehensive items
|
— | — | — | — | — | — | — | — | ||||||||||||||||||||||||
Other
|
— | — | (0.8 | ) | — | — | — | — | (0.8 | ) | ||||||||||||||||||||||
Balance at September 28, 2013
|
419.0 | $ | 419.0 | $ | 10,812.5 | $ | 8,465.7 | (57.6 | ) | $ | (3,109.5 | ) | $ | (150.4 | ) | $ | 16,437.3 | |||||||||||||||
Balance at December 31, 2013
|
369.6 | $ | 369.6 | $ | 8,222.6 | $ | 8,753.3 | (7.6 | ) | $ | (412.2 | ) | $ | (77.2 | ) | $ | 16,856.1 | |||||||||||||||
Issuance of shares under employees'
and directors' stock plans
|
3.5 | 3.5 | 139.0 | — | (0.4 | ) | (43.2 | ) | — | 99.3 | ||||||||||||||||||||||
Issuance of shares
|
34.9 | 34.9 | 2,907.4 | — | — | — | — | 2,942.3 | ||||||||||||||||||||||||
Stock-based compensation
|
— | — | 86.6 | — | — | — | — | 86.6 | ||||||||||||||||||||||||
Tax benefit related to employees'
and directors' stock plans
|
— | — | 60.9 | — | — | — | — | 60.9 | ||||||||||||||||||||||||
Dividends declared
|
— | — | — | (180.5 | ) | — | — | — | (180.5 | ) | ||||||||||||||||||||||
Net income
|
— | — | — | 1,293.2 | — | — | — | 1,293.2 | ||||||||||||||||||||||||
Other comprehensive items
|
— | — | — | — | — | — | (647.1 | ) | (647.1 | ) | ||||||||||||||||||||||
Other
|
— | — | (0.2 | ) | — | — | — | — | (0.2 | ) | ||||||||||||||||||||||
Balance at September 27, 2014
|
408.0 | $ | 408.0 | $ | 11,416.3 | $ | 9,866.0 | (8.0 | ) | $ | (455.4 | ) | $ | (724.3 | ) | $ | 20,510.6 |
Nature of Operations
|
Thermo Fisher Scientific Inc. (the company or Thermo Fisher) enables customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. Markets served include pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. On February 3, 2014, the company acquired Life Technologies Corporation (Note 2).
|
The interim consolidated financial statements presented herein have been prepared by the company, are unaudited and, in the opinion of management, reflect all adjustments of a normal recurring nature necessary for a fair presentation of the financial position at September 27, 2014, the results of operations for the three- and nine-month periods ended September 27, 2014, and September 28, 2013, and the cash flows for the nine-month periods ended September 27, 2014, and September 28, 2013. Interim results are not necessarily indicative of results for a full year.
|
The consolidated balance sheet presented as of December 31, 2013, has been derived from the audited consolidated financial statements as of that date. The consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual financial statements and notes of the company. The consolidated financial statements and notes included in this report should be read in conjunction with the 2013 financial statements and notes included in the company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (SEC) on May 2, 2014.
|
Note 1 to the consolidated financial statements for 2013 describes the significant accounting estimates and policies used in preparation of the consolidated financial statements. There have been no material changes in the company’s significant accounting policies during the nine months ended September 27, 2014.
|
|
Product warranties are included in other accrued expenses in the accompanying balance sheet. The changes in the carrying amount of warranty obligations are as follows:
|
Nine Months Ended
|
||||||||
September 27,
|
September 28,
|
|||||||
(In millions)
|
2014
|
2013
|
||||||
Beginning Balance
|
$ | 49.8 | $ | 48.7 | ||||
Provision charged to income
|
57.6 | 51.8 | ||||||
Usage
|
(58.0 | ) | (54.2 | ) | ||||
Acquisitions
|
7.1 | — | ||||||
Adjustments to previously provided warranties, net
|
1.0 | 0.7 | ||||||
Other, net
|
(1.3 | ) | — | |||||
Ending Balance
|
$ | 56.2 | $ | 47.0 |
The components of inventories are as follows:
|
September 27,
|
December 31,
|
|||||||
(In millions)
|
2014
|
2013
|
||||||
Raw Materials
|
$ | 444.3 | $ | 347.4 | ||||
Work in Process
|
216.9 | 157.7 | ||||||
Finished Goods
|
1,252.5 | 989.4 | ||||||
Inventories
|
$ | 1,913.7 | $ | 1,494.5 | ||||
Property, plant and equipment consists of the following:
|
September 27,
|
December 31,
|
|||||||
(In millions)
|
2014
|
2013
|
||||||
Land
|
$ | 287.2 | $ | 212.2 | ||||
Buildings and Improvements
|
996.6 | 821.0 | ||||||
Machinery, Equipment and Leasehold Improvements
|
2,550.3 | 2,047.9 | ||||||
Property, Plant and Equipment, at Cost
|
3,834.1 | 3,081.1 | ||||||
Less: Accumulated Depreciation and Amortization
|
1,428.0 | 1,313.7 | ||||||
Property, Plant and Equipment, at Cost, Net
|
$ | 2,406.1 | $ | 1,767.4 | ||||
Acquisition-related intangible assets are as follows:
|
September 27, 2014
|
December 31, 2013
|
|||||||||||||||||||||||
Accumulated
|
Accumulated
|
|||||||||||||||||||||||
(In millions)
|
Gross
|
Amortization
|
Net
|
Gross
|
Amortization
|
Net
|
||||||||||||||||||
Definite Lived
|
$ | 18,483.2 | $ | (5,088.9 | ) | $ | 13,394.3 | $ | 10,121.8 | $ | (4,388.2 | ) | $ | 5,733.6 | ||||||||||
Indefinite Lived
|
1,304.0 | — | 1,304.0 | 1,337.7 | — | 1,337.7 | ||||||||||||||||||
Acquisition-related Intangible Assets
|
$ | 19,787.2 | $ | (5,088.9 | ) | $ | 14,698.3 | $ | 11,459.5 | $ | (4,388.2 | ) | $ | 7,071.3 |
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In addition, significant estimates were made in estimating future cash flows to assess potential impairment of assets and in determining the fair value of acquired intangible assets (Note 2) and the ultimate loss from abandoning leases at facilities being exited (Note 14). Actual results could differ from those estimates.
|
Recent Accounting Pronouncements
|
In May 2014, the FASB issued new revenue recognition guidance which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. The new standard also requires significantly expanded disclosures regarding the qualitative and quantitative information of an entity's nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The guidance is effective for the company in 2017. Early adoption is not permitted. The company is currently evaluating the impact the standard will have on its consolidated financial statements.
|
In April 2014, the FASB issued new guidance on reporting discontinued operations and disclosures of disposals. Under the new guidance, only disposals representing a strategic shift in operations will be presented as discontinued operations. The new guidance also requires disclosure of the pre-tax income attributable to a disposal of a significant part of the company that does not qualify for discontinued operations reporting. This guidance is effective for the company in 2015. Adoption of this standard is not expected to have a material impact on the company’s consolidated financial statements.
|
The company’s acquisitions have historically been made at prices above the fair value of the acquired identifiable assets, resulting in goodwill, due to expectations of the synergies that will be realized by combining the businesses. These synergies include the elimination of redundant facilities, functions and staffing; use of the company’s existing commercial infrastructure to expand sales of the acquired businesses’ products; and use of the commercial infrastructure of the acquired businesses to cost-effectively expand sales of company products.
|
Acquisitions have been accounted for using the purchase method of accounting, and the acquired companies’ results have been included in the accompanying financial statements from their respective dates of acquisition. Acquisition transaction costs are recorded in selling, general and administrative expenses as incurred.
|
On February 3, 2014, the company completed the acquisition of Life Technologies Corporation, within the Life Sciences Solutions segment, for a total purchase price of $15.30 billion, net of cash acquired, including the assumption of $2.28 billion of debt. The company issued debt and common stock in late 2013 and early 2014 to partially fund the acquisition (Notes 9 and 11). Life Technologies provides innovative products and services to customers conducting scientific research and genetic analysis, as well as those in applied markets, such as forensics and food safety testing. The acquisition of Life Technologies extends customer reach and broadens the company’s offerings in biosciences; genetic, medical and applied sciences; and bioproduction. Life Technologies’ revenues totaled $3.87 billion in 2013. The purchase price exceeded the fair value of the identifiable net assets and, accordingly, $7.15 billion was allocated to goodwill, substantially none of which is tax deductible.
|
In addition, in 2014, the company acquired an animal health diagnostics company, within the Life Sciences Solutions segment, and a distributor of analytical instruments, within the Analytical Instruments segment, for an aggregate of $36 million, net of cash acquired.
|
(In millions)
|
Life Technologies
|
Other
|
Total
|
|||||||||
Purchase Price
|
||||||||||||
Cash paid
|
$ | 13,487.3 | $ | 43.3 | $ | 13,530.6 | ||||||
Debt assumed
|
2,279.5 | — | 2,279.5 | |||||||||
Purchase price payable
|
— | 4.0 | 4.0 | |||||||||
Cash acquired
|
(463.0 | ) | (11.5 | ) | (474.5 | ) | ||||||
$ | 15,303.8 | $ | 35.8 | $ | 15,339.6 | |||||||
Net Assets Acquired
|
||||||||||||
Current assets
|
$ | 1,759.0 | $ | 18.5 | $ | 1,777.5 | ||||||
Property, plant and equipment
|
751.8 | 1.1 | 752.9 | |||||||||
Definite-lived intangible assets:
|
||||||||||||
Customer relationships
|
5,883.0 | 7.0 | 5,890.0 | |||||||||
Product technology
|
2,626.9 | 5.5 | 2,632.4 | |||||||||
Tradenames and other
|
619.1 | — | 619.1 | |||||||||
Indefinite-lived intangible assets:
|
||||||||||||
In-process research and development
|
58.4 | — | 58.4 | |||||||||
Goodwill
|
7,153.1 | 12.5 | 7,165.6 | |||||||||
Other assets
|
252.3 | 0.1 | 252.4 | |||||||||
Liabilities assumed
|
(3,799.8 | ) | (8.9 | ) | (3,808.7 | ) | ||||||
$ | 15,303.8 | $ | 35.8 | $ | 15,339.6 |
The weighted-average amortization periods for intangible assets acquired in 2014 are 16 years for customer relationships, 11 years for product technology and 11 years for definite-lived tradenames and other. The weighted average amortization period for all definite-lived intangible assets acquired in 2014 is 14 years.
|
The net assets acquired included in the table above have been recorded based on estimates of fair value, as revised for certain measurement period adjustments as follows. In the third quarter of 2014, the company completed the valuation of the identifiable intangibles acquired in the acquisition of Life Technologies. Following completion of the valuation, the company adjusted the values of certain acquired intangible assets, primarily tradenames, recorded in the first quarter of 2014 and changed the characterization to definite-lived from indefinite-lived as follows:
|
(In millions)
|
Increase (Decrease) from Initial Valuation
|
|||
Indefinite-lived Tradenames
|
$ | (448.2 | ) | |
Definite-lived Intangible Assets:
|
||||
Tradenames
|
378.5 | |||
Customer relationships
|
19.0 | |||
Product technology
|
2.3 | |||
Goodwill
|
30.8 | |||
Deferred Tax Liabilities
|
(17.6 | ) |
Unaudited Pro Forma Information
|
The company acquired Life Technologies in February 2014. Revenues of Life Technologies after the date of acquisition are included in the accompanying statement of income and totaled approximately $0.94 billion and $2.56 billion in the three and nine months ended September 27, 2014, respectively. Immediately upon the closing of the acquisition, the company began integrating Life Technologies and as such the legacy and acquired businesses are now sharing various selling, general and administrative functions. As a result, computing a separate measure of Life Technologies’ stand-alone profitability for periods after the acquisition date is not practical.
|
Had the acquisition of Life Technologies been completed as of the beginning of 2013, the company’s pro forma results for 2014 and 2013 would have been as follows:
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||
September 28,
|
September 27,
|
September 28,
|
||||||||||
(In millions except per share amounts)
|
2013
|
2014
|
2013
|
|||||||||
Revenues
|
$ | 4,153.6 | $ | 12,675.0 | $ | 12,422.3 | ||||||
Income from Continuing Operations
|
$ | 286.8 | $ | 1,590.9 | $ | 567.6 | ||||||
Net Income
|
$ | 286.6 | $ | 1,592.6 | $ | 562.6 | ||||||
Earnings per Share from Continuing Operations:
|
||||||||||||
Basic
|
$ | 0.72 | $ | 3.99 | $ | 1.44 | ||||||
Diluted
|
$ | 0.72 | $ | 3.95 | $ | 1.43 | ||||||
Earnings per Share:
|
||||||||||||
Basic
|
$ | 0.72 | $ | 3.99 | $ | 1.43 | ||||||
Diluted
|
$ | 0.72 | $ | 3.95 | $ | 1.41 |
·
|
·
|
·
|
·
|
·
|
June 28,
|
||||
(In millions)
|
2014
|
|||
Current Assets
|
$ | 39.5 | ||
Long-term Assets
|
400.3 | |||
Current Liabilities
|
15.5 | |||
Long-term Liabilities
|
84.1 | |||
December 31,
|
||||
(In millions)
|
2013
|
|||
Current Assets
|
$ | 74.3 | ||
Long-term Assets
|
229.3 | |||
Current Liabilities
|
6.4 | |||
Long-term Liabilities
|
22.0 | |||
·
|
The new Life Sciences Solutions segment consists of the majority of the former Life Technologies businesses and Thermo Fisher biosciences businesses.
|
·
|
Thermo Fisher’s global chemicals business has moved from the biosciences business in the Analytical Technologies segment to the Laboratory Products and Services segment.
|
·
|
Thermo Fisher’s Analytical Technologies segment has been renamed the Analytical Instruments segment to reflect the transfer of the biosciences businesses to other segments, as mentioned above.
|
·
|
Two small specialty diagnostics businesses within Life Technologies have become part of the Specialty Diagnostics segment.
|
Business Segment Information
|
||||||||||||||||
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
September 27,
|
September 28,
|
September 27,
|
September 28,
|
|||||||||||||
(In millions)
|
2014
|
2013
|
2014
|
2013
|
||||||||||||
Revenues
|
||||||||||||||||
Life Sciences Solutions
|
$ | 1,071.9 | $ | 167.2 | $ | 3,010.5 | $ | 520.8 | ||||||||
Analytical Instruments
|
786.5 | 765.4 | 2,349.8 | 2,266.5 | ||||||||||||
Specialty Diagnostics
|
811.8 | 759.3 | 2,480.6 | 2,358.5 | ||||||||||||
Laboratory Products and Services
|
1,628.7 | 1,594.7 | 4,918.6 | 4,746.0 | ||||||||||||
Eliminations
|
(127.5 | ) | (94.8 | ) | (362.7 | ) | (268.4 | ) | ||||||||
Consolidated revenues
|
4,171.4 | 3,191.8 | 12,396.8 | 9,623.4 | ||||||||||||
Segment Income (a)
|
||||||||||||||||
Life Sciences Solutions
|
306.3 | 38.9 | 850.0 | 123.4 | ||||||||||||
Analytical Instruments
|
137.8 | 131.0 | 399.1 | 376.8 | ||||||||||||
Specialty Diagnostics
|
224.3 | 204.2 | 681.7 | 643.4 | ||||||||||||
Laboratory Products and Services
|
246.6 | 245.3 | 738.3 | 714.7 | ||||||||||||
Subtotal reportable segments (a)
|
915.0 | 619.4 | 2,669.1 | 1,858.3 | ||||||||||||
Cost of revenues charges
|
(2.1 | ) | (0.9 | ) | (326.7 | ) | (27.2 | ) | ||||||||
Selling, general and administrative charges, net
|
(20.3 | ) | (24.0 | ) | (118.0 | ) | (47.9 | ) | ||||||||
Restructuring and other (costs) income, net
|
110.6 | (11.4 | ) | 631.9 | (54.4 | ) | ||||||||||
Amortization of acquisition-related intangible assets
|
(362.9 | ) | (191.0 | ) | (992.4 | ) | (574.2 | ) | ||||||||
Consolidated operating income
|
640.3 | 392.1 | 1,863.9 | 1,154.6 | ||||||||||||
Other expense, net (b)
|
(101.1 | ) | (73.1 | ) | (313.8 | ) | (212.7 | ) | ||||||||
Income from continuing operations before income taxes
|
$ | 539.2 | $ | 319.0 | $ | 1,550.1 | $ | 941.9 | ||||||||
Depreciation
|
||||||||||||||||
Life Sciences Solutions
|
$ | 37.1 | $ | 4.3 | $ | 97.4 | $ | 12.5 | ||||||||
Analytical Instruments
|
9.4 | 10.5 | 29.0 | 30.5 | ||||||||||||
Specialty Diagnostics
|
19.4 | 18.3 | 57.4 | 54.9 | ||||||||||||
Laboratory Products and Services
|
26.9 | 26.3 | 79.9 | 78.5 | ||||||||||||
Consolidated depreciation
|
$ | 92.8 | $ | 59.4 | $ | 263.7 | $ | 176.4 |
(a) | Represents operating income before certain charges to cost of revenues and selling, general and administrative expenses; restructuring and other costs, net; and amortization of acquisition-related intangibles. |
(b) | The company does not allocate other expense, net to its segments. |
The components of other expense, net, in the accompanying statement of income are as follows:
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
September 27,
|
September 28,
|
September 27,
|
September 28,
|
|||||||||||||
(In millions)
|
2014
|
2013
|
2014
|
2013
|
||||||||||||
Interest Income
|
$ | 10.5 | $ | 7.1 | $ | 38.4 | $ | 21.4 | ||||||||
Interest Expense
|
(116.8 | ) | (64.3 | ) | (363.7 | ) | (193.1 | ) | ||||||||
Other Items, Net
|
5.2 | (15.9 | ) | 11.5 | (41.0 | ) | ||||||||||
Other Expense, Net
|
$ | (101.1 | ) | $ | (73.1 | ) | $ | (313.8 | ) | $ | (212.7 | ) | ||||
|
In the first nine months of 2014, other items, net includes $9 million of gains from the sale of equity and available-for-sale investments. In the first nine months of 2013, other items, net includes $61 million of charges related to amortization of fees paid to obtain bridge financing commitments related to the acquisition of Life Technologies, offset in part by a $5 million gain from additional proceeds from the prior sale of an equity investment. In the first quarter of 2013, the company irrevocably contributed appreciated available-for-sale investments that had a fair value of $27 million to two of its U.K. defined benefit plans, resulting in realization of a previously unrecognized gain of $11 million.
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
September 27,
|
September 28,
|
September 27,
|
September 28,
|
|||||||||||||
(In millions)
|
2014
|
2013
|
2014
|
2013
|
||||||||||||
Stock Option Awards
|
$ | 11.7 | $ | 10.4 | $ | 34.1 | $ | 30.6 | ||||||||
Restricted Unit Awards
|
18.9 | 12.5 | 52.5 | 36.0 | ||||||||||||
Total Stock-based Compensation Expense
|
$ | 30.6 | $ | 22.9 | $ | 86.6 | $ | 66.6 |
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
September 27,
|
September 28,
|
September 27,
|
September 28,
|
|||||||||||||
(In millions)
|
2014
|
2013
|
2014
|
2013
|
||||||||||||
Service Cost-Benefits Earned
|
$ | 8.0 | $ | 5.8 | $ | 17.6 | $ | 15.2 | ||||||||
Interest Cost on Benefit Obligation
|
23.6 | 11.9 | 67.2 | 35.8 | ||||||||||||
Expected Return on Plan Assets
|
(25.0 | ) | (13.3 | ) | (71.2 | ) | (39.7 | ) | ||||||||
Amortization of Actuarial Net Loss
|
1.9 | 2.8 | 5.9 | 8.5 | ||||||||||||
Amortization of Prior Service Benefit
|
— | — | (0.1 | ) | (0.2 | ) | ||||||||||
Special Termination Benefits
|
0.2 | 0.7 | 0.2 | 1.2 | ||||||||||||
Net Periodic Benefit Cost
|
$ | 8.7 | $ | 7.9 | $ | 19.6 | $ | 20.8 |
Nine Months Ended
|
||||||||
September 27,
|
September 28,
|
|||||||
(In millions)
|
2014
|
2013
|
||||||
Provision for Income Taxes at Statutory Rate
|
$ | 542.5 | $ | 329.7 | ||||
Increases (Decreases) Resulting From:
|
||||||||
Foreign rate differential
|
(187.6 | ) | (178.0 | ) | ||||
Impact of change in tax laws and apportionment on deferred taxes
|
(26.0 | ) | (5.0 | ) | ||||
Foreign and research and development tax credits
|
(122.5 | ) | (118.6 | ) | ||||
Manufacturing deduction
|
(26.6 | ) | (21.1 | ) | ||||
State income taxes, net of federal tax
|
27.7 | (3.1 | ) | |||||
Nondeductible expenses
|
9.6 | 5.3 | ||||||
Provision of tax reserves, net
|
25.3 | — | ||||||
Tax return reassessments and settlements
|
(1.5 | ) | — | |||||
Basis difference on disposal of businesses
|
26.3 | — | ||||||
Singapore tax holiday
|
(10.3 | ) | — | |||||
Other, net
|
1.7 | (3.4 | ) | |||||
$ | 258.6 | $ | 5.8 | |||||
The company has significant activities in Singapore and has received considerable tax incentives. The local taxing authority granted the company pioneer company status which provides an incentive encouraging companies to undertake activities that have the effect of promoting economic or technological development in Singapore. This incentive equates to a tax exemption on earnings associated with most of the company’s manufacturing activities in Singapore and continues through December 31, 2021. The impact of this tax holiday decreased the annual effective tax rate by 0.7% and increased diluted earnings per share by approximately $0.03 for the nine months ended September 27, 2014.
|
The company’s unrecognized tax benefits increased to $259.8 million at September 27, 2014, from $134.2 million at December 31, 2013. Of the total increase, $100.3 million resulted from the acquisition of Life Technologies and $54.4 million resulted from the provision of tax reserves, primarily related to the sale of the divested businesses and a tax matter in a foreign jurisdiction, offset in part by a reduction of $29.1 million from resolution of a tax matter for which a reserve had previously been established.
|
Three Months Ended
|
Nine Months Ended
|
|||||||||||||||
September 27,
|
September 28,
|
September 27,
|
September 28,
|
|||||||||||||
(In millions except per share amounts)
|
2014
|
2013
|
2014
|
2013
|
||||||||||||
Income from Continuing Operations
|
$ | 469.9 | $ | 317.7 | $ | 1,291.5 | $ | 936.1 | ||||||||
Gain (Loss) from Discontinued Operations
|